Efficient high-throughput screening by ER Ca measurement to identify inhibitors of ryanodine receptor Ca-release channels

Department of Pharmacology, Juntendo University School of Medicine, Tokyo, Japan (T.M., N.K., Y.S., R.A., T.S.); Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan (M.I.-Y., S.M., H.K); Institute for Quantitative Biosciences, The University of Tokyo, Tokyo, Japan (H.Og.); Department of Cellular and Molecular Pharmacology, Graduate School of Medicine, The University of Tokyo, Tokyo Japan (J.S., K.K., M.I.); Division of Cellular and Molecular Pharmacology, Nihon University School of Medicine, Tokyo, Japan (K.K., M.I.); and Department of Pharmacology, School of Medicine, Showa University, Tokyo, Japan (H.Oy., Y.K.). This article has not been copyedited and formatted. The final version may differ from this version. Molecular Pharmacology Fast Forward. Published on April 19, 2018 as DOI: 10.1124/mol.117.111468

[1]  Y. Yoshizaki,et al.  Drug-Repositioning Screening for Keap1-Nrf2 Binding Inhibitors using Fluorescence Correlation Spectroscopy , 2017, Scientific Reports.

[2]  D. Bers,et al.  High-Throughput Screens to Discover Small-Molecule Modulators of Ryanodine Receptor Calcium Release Channels , 2017, SLAS discovery : advancing life sciences R & D.

[3]  M. Iino,et al.  Genotype–Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel , 2016, Human mutation.

[4]  M. Iino,et al.  Divergent Activity Profiles of Type 1 Ryanodine Receptor Channels Carrying Malignant Hyperthermia and Central Core Disease Mutations in the Amino-Terminal Region , 2015, PloS one.

[5]  Masamichi Ohkura,et al.  Imaging intraorganellar Ca2+ at subcellular resolution using CEPIA , 2014, Nature Communications.

[6]  D. V. van Helden,et al.  Three independent mechanisms contribute to tetracaine inhibition of cardiac calcium release channels. , 2011, Journal of molecular and cellular cardiology.

[7]  H. Duff,et al.  Carvedilol and its new analogs suppress arrhythmogenic store overload–induced Ca2+ release , 2011, Nature Medicine.

[8]  Silvia G Priori,et al.  Inherited dysfunction of sarcoplasmic reticulum Ca2+ handling and arrhythmogenesis. , 2011, Circulation research.

[9]  J. Dixon,et al.  Pharmacological Targeting of the Mitochondrial Phosphatase PTPMT1 , 2010, Journal of Pharmacology and Experimental Therapeutics.

[10]  F. Muntoni,et al.  Congenital muscle disorders with cores: the ryanodine receptor calcium channel paradigm. , 2008, Current opinion in pharmacology.

[11]  I. Stibor,et al.  A role of the 9-aminoacridines and their conjugates in a life science. , 2007, Current protein & peptide science.

[12]  R. Robinson,et al.  Mutations in RYR1 in malignant hyperthermia and central core disease , 2006, Human mutation.

[13]  Joseph D. Mocanu,et al.  Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent , 2006, Molecular Cancer Therapeutics.

[14]  A. J. Williams,et al.  Electrostatic mechanisms underlie neomycin block of the cardiac ryanodine receptor channel (RyR2). , 2004, Biophysical journal.

[15]  D. Bers.  Macromolecular complexes regulating cardiac ryanodine receptor function. , 2004, Journal of molecular and cellular cardiology.

[16]  Michael Fill,et al.  Ryanodine receptor calcium release channels. , 2002, Physiological reviews.

[17]  J. Costentin,et al.  Behavioural and neurochemical evidence that the antimicrobial agent oxolinic acid is a dopamine uptake inhibitor , 1998, European Neuropsychopharmacology.

[18]  J. Ma,et al.  Block by ruthenium red of the ryanodine-activated calcium release channel of skeletal muscle , 1993, The Journal of general physiology.

[19]  E. Myhr,et al.  Temperature-dependent in vitro antimicrobial activity of four 4-quinolones and oxytetracycline against bacteria pathogenic to fish , 1992, Antimicrobial Agents and Chemotherapy.

[20]  D. J. Reed,et al.  Calcium chelation induced glutathione efflux from tumor cells and prevention by ruthenium red or neomycin. , 1991, Biochemical and biophysical research communications.

[21]  R. Gleckman,et al.  Drug therapy reviews: oxolinic acid. , 1979, American journal of hospital pharmacy.

[22]  R. Genco,et al.  In vitro antiplaque properties of a series of alkyl bis(biguanides). , 1978, Journal of medicinal chemistry.

[23]  G. Meissner,et al.  Ryanodine receptor/Ca2+ release channels and their regulation by endogenous effectors. , 1994, Annual review of physiology.

[24]  Y. Ogawa.  Role of ryanodine receptors. , 1994, Critical reviews in biochemistry and molecular biology.

[25]  S. Györke,et al.  Involvement of sarcoplasmic reticulum ‘Ca2+ release channels’ in excitation‐contraction coupling in vertebrate skeletal muscle. , 1992, The Journal of physiology.

[26]  P. Palade.  Drug-induced Ca'' Release from Isolated Sarcoplasmic Reticulum , 1987 .

[27]  M. L. Horne,et al.  Dantrolene in human malignant hyperthermia. , 1982, Anesthesiology.

[28]  N. Cozzarelli.  The mechanism of action of inhibitors of DNA synthesis. , 1977, Annual review of biochemistry.